By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    HIPPA compliance
    How Medical Office Staff Can Make Your Practice HIPAA Compliant
    October 29, 2021
    Everything you need to know about hyaluronic acid treatment
    Everything you need to know about hyaluronic acid treatment
    February 10, 2022
    Which Mushroom Capsules Are Good for Your Health?
    May 5, 2022
    Latest News
    7 Most Common Healthcare Accreditation Programs: Which Should You Use?
    August 20, 2025
    Hospital Pest Control and the Fight Against Superbugs
    August 20, 2025
    Hygiene Beyond The Clinic: Attention To Overlooked Non-Clinical Spaces
    August 13, 2025
    5 Steps to a Promising Career as a Healthcare Administrator
    August 3, 2025
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    hearing aid market
    Can You Hear Me Now? Another Health Market that Really Works
    November 21, 2013
    Food Biotechnology – Genetically Modified Food Controversies and Health
    February 27, 2018
    Bioethics Commission Calls for More Communication, Proactivity When Dealing with Incidental Findings
    December 14, 2013
    Latest News
    How Social Security Disability Shapes Access to Care and Everyday Health
    August 20, 2025
    How a DUI Lawyer Can Help When Your Future Health Feels Uncertain
    August 20, 2025
    How One Fall Can Lead to a Long Road of Medical Complications
    August 20, 2025
    How IT and Marketing Teams Can Collaborate to Protect Patient Trust
    July 17, 2025
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Is pharma industry too meek on pricing?
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Hospital Administration > Is pharma industry too meek on pricing?
Hospital AdministrationMedical EthicsTechnologyWellness

Is pharma industry too meek on pricing?

DavidEWilliams
DavidEWilliams
Share
6 Min Read
SHARE
ID-100146535

What were we thinking?

ID-100146535

What were we thinking?

The biopharmaceutical industry has been under attack for some time for the high and rising prices of its products. Pressure has increased recently with the arrival of costly medications for oncology, hepatitis, high cholesterol and more. Expect even further pressure as more specialty drugs are introduced, and then really significant pushback once seriously costly innovations such as gene therapy come online.

I’ve noticed that the pool of people complaining about drug pricing is widening. Now, even doctors are picking up the megaphone. For example, the American College of Physicians (ACP) recently made the case for drug price controls in a position paper. Recommendations include requiring companies to disclose R&D and materials costs, allowing the use of Quality Adjusted Life Years (QALYs) in research funded by the Patient-Centered Outcomes Research Institute (PCORI), having Medicare negotiate prices, enabling reimportation of drugs from lower-priced markets, ensuring that restrictive formularies don’t price patients out of the market by requiring excessive cost sharing, etc.

For all its spending and glitz, the industry’s main lobbyist (PhRMA) hasn’t managed to stave off the attacks. In fact some of its past and current arguments are digging the industry into a deeper hole. Here’s what PhRMA said in response to a MedPage Today inquiry on the ACP position paper:

In an email to MedPage Today, a spokesperson for the Pharmaceutical Research and Manufacturers of America (PhRMA) called the recommendations “far-reaching,” and “driven by the false notion that spending on medicines is fueling overall healthcare cost growth.”

There are a couple of important things the industry is doing wrong:

PhRMA has placed huge emphasis on how expensive it is to develop a drug, and strongly implied that drug prices are based on the costs of R&D. The general public more or less accepted the old $1 billion per drug benchmark, but I’m not sure even the industry believes the $2.6 billion for a new drug figure PhRMA has been using since 2014. And –just like in other industries– manufacturers don’t set prices based on what they spent on R&D.

So while PhRMA may complain about requests for “transparency” on R&D spending –and I agree this information is worthless, not to mention time consuming and expensive to collect– the industry brought the issue on itself.

As the email to MedPage shows, PhRMA’s current argument is that drugs are not driving up total medical costs. In other words, money spent to pay for new drugs is saved elsewhere in the system, for example by reducing hospitalizations, doctor visits or surgeries.

This cost-saving/cost-neutral argument demonstrates to me that PhRMA has not learned its lesson from the failure of its R&D spending-based approach for sympathy. The R&D approach implies a willingness to live with “cost plus” pricing. And the cost-saving argument ignores the possibility that a drug is not just a cheaper alternative to existing approaches but actually a better one. For example, the value of a cure for Hepatitis C extends beyond the financial cost of a liver transplant.

Here are a few suggestions for PhRMA:

  • Embrace the concept of Quality Adjusted Life Years (QALY) to measure the value of an intervention. But don’t settle for the arbitrary $50,000 threshold that researchers often use to judge whether a therapy is worthwhile.
  • Push back against the ACP and other physician critics of pharma pricing by insisting that the QALY approach be used to measure not just pharma but the work that the rest of the healthcare system does. The QALY concept can be applied to procedures, devices and maybe to hospitalizations and office visits. A lot of what’s done in healthcare today can’t demonstrate any value on the QALY scale, so maybe those things should be eliminated or have their reimbursements cut in order to increase affordability or make room for better interventions.
  • Prepare the public for more costly innovations like gene therapy, which have the potential to be transformative for sick individuals but are very expensive. If I or someone else in my family is sick, I want the system to find a way to afford the innovation even if it doesn’t save costs anywhere else.

This is a tricky topic and I’ve just scratched the surface here. But bottom line PhRMA should at least prepare us for the possibility that its members will add to total costs, and that we should be ok with that outcome if the results are good enough.

Image courtesy of Stuart Miles at FreeDigitalPhotos.net

—-

By healthcare business consultant David E. Williams, president of Health Business Group.

 

TAGGED:drug pricingpharmaceuticals
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

engineer fitting prosthetic arm
How Social Security Disability Shapes Access to Care and Everyday Health
Health care
August 20, 2025
a woman explaining the document
How a DUI Lawyer Can Help When Your Future Health Feels Uncertain
Public Health
August 20, 2025
physiotherapist at work
How One Fall Can Lead to a Long Road of Medical Complications
Health care
August 20, 2025
Common Healthcare Accreditation Programs
7 Most Common Healthcare Accreditation Programs: Which Should You Use?
Health News
August 20, 2025

You Might also Like

Chancellor Hints at Regenerative Medicine #regenmed Anouncement

November 10, 2012
eHealthMedical InnovationsMobile HealthTechnology

What You Need to Know About Mobile Health Apps in 2018

December 1, 2017
benefits of EHR systems in healthcare
Technology

Using EHR systems in healthcare for Cost-Effective Services

February 9, 2023

Startup Founder Reacquires His Patient Portal Business

August 27, 2013
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?